Filter exchange imaging as a novel MRI biomarker - getting ready for clinical
Reference number | |
Coordinator | CR DEVELOPMENT AB |
Funding from Vinnova | SEK 2 289 000 |
Project duration | January 2014 - December 2016 |
Status | Completed |
Important results from the project
The majority of MRI biomarkers suffer from low diagnostic specificity. Filter EXchange Imaging (FEXI) and MIcroscopic Anisotropy Imaging (MIAI) are novel non-invasive MRI methods capable of capturing unique tissue information in vivo. This project aims at scrutinizing the full potential of FEXI and MIAI, extending the theoretical frameworks and achieving an optimal experimental protocol for a clinical study of MS patients. Furthermore, this project intends to build a research platform for the development and testing of the next generation of diffusion MRI methods.
Expected long term effects
Significant theoretical insights and methodological advancements were achieved. We now understand the effects of imaging gradients and tissue anisotropy in FEXI. The study also resulted in an extended MIAI protocol, which was applied to study maturation in fixed monkey brain. FEXI and MIAI are ready for a clinical study of MS, which has started. The project allowed realizing a strong synergy between DIG, CRD and an extended group of collaborators.
Approach and implementation
This project facilitated strong collaborations between CRD, DIG, Lund University and other sites, forming a platform for development of new methods. The DIGs facilities provided an efficient and fruitful environment to refine and optimize novel methods through iteration between theory and preclinical and clinical experiments. The collaboration allowed addressing relevant scientific questions, such as understanding the microstructure of the maturating brain, or clinical investigations of the MS.